This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Intellectual Property

Aug. 6, 2015

Federal Circuit affirms validity of patents for lucrative Allergan drug

Allergan Inc.'s exclusive rights to a lucrative drug were affirmed Tuesday when the U.S. Court of Appeals for the Federal Circuit ruled the company's patents for Lumigan, an eye medication, are valid.


By Phil Johnson


Daily Journal Staff Writer


Allergan Inc.'s exclusive rights to a lucrative drug were affirmed Tuesday when the
U.S. Court of Appeals for the Federal Circuit ruled the company's patents for Lumigan,
an eye medication, are valid.


The three-judge panel affirmed a 2013 ruling by U.S. District Judge Michael H. Schneider
of the Eastern Dist...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up